Lates News

According to the AI Express news, Donghai Securities issued a research report on May 13th, giving Linyi Pharmaceutical (600285.SH) a buy rating. The main reasons for the rating include: 1) the steady growth of patches and rapid increase in tablet sales; 2) the steady improvement of profitability; 3) the acquisition of Yinguyi Pharmaceutical, enriching the product matrix. (Daily Economic News)